Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study

Table 2 Oral antidiabetic therapy

Type of therapy	n (%)
Total number of patients	3648
Metformin + vildagliptin	603 (16.5)
Metformin + vildagliptin (SPC)	2198 (60.3)
Metformin + sulfonylureas	370 (10.1)
Glibenclamide/metformin	96 (2.6)
Glimepiride/metformin	241 (6.6)
Gliquidone/metformin	1 (< 0.1)
Nateglinide/metformin	2 (0.1)
Repaglinide/metformin	30 (0.8)
Metformin + glitazones	123 (3.4)
Pioglitazone/metformin	99 (2.7)
Rosiglitazone/metformin	24 (0.7)
Metformin + other DPP-4 inhibitors	99 (2.7)
Saxagliptin/metformin	7 (0.2)
Sitagliptin/metformin	92 (2.5)
Other1	255 (7.0)

¹The group “other” also included patients for whom data were documented in this observational study without the physician recording information on the medication given and patients for whom the physician recorded only one medication although only patients receiving dual therapy were to be documented in this study. SPC: Single pill combination; DPP-4: Dipeptidyl peptidase-4.